FilingIndex
← The Wire
NBIXNasdaq

NEUROCRINE BIOSCIENCES INC

Biological Products, (No Diagnostic Substances) · DE · CIK 914475

Neurocrine Biosciences discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders

red 8-K · 90d
$16.06B
Market cap
$170.00
Last close
+0.9%
1D
+5.2%
5D
1.4M
Volume
Price · last 39 sessions+26.8%
May 4L $134.07 · H $170.00Jun 29
159
Total filings
May 28, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 28, 20268-KMaterial Agreement · Acquisition / DispositionMay 18, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 15, 2026DEF 14ADEF 14AApr 15, 20268-KMaterial AgreementApr 6, 202610-K10-KFeb 11, 20268-KResults of OperationsFeb 11, 20268-KExecutive ChangeNov 24, 202510-Q10-QOct 28, 20258-KResults of OperationsOct 28, 202510-Q10-QJul 30, 20258-KResults of OperationsJul 30, 20258-KExecutive ChangeMay 30, 20258-KExecutive Change · Shareholder VoteMay 22, 202510-Q10-QMay 5, 20258-KResults of OperationsMay 5, 2025DEFA14ADEFA14AApr 9, 2025DEF 14ADEF 14AApr 9, 20258-KExecutive Change · Reg FD DisclosureApr 4, 202510-K10-KFeb 10, 20258-KResults of OperationsFeb 6, 20258-KMaterial Agreement · Reg FD DisclosureJan 27, 20258-KCompany UpdateDec 20, 20248-KCompany UpdateNov 1, 202410-Q10-QOct 30, 20248-KResults of OperationsOct 30, 20248-KExecutive ChangeOct 11, 20248-KReg FD Disclosure · Company UpdateAug 28, 202410-Q10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KExecutive Change · Bylaw AmendmentMay 28, 20248-KExecutive Change · Shareholder VoteMay 23, 202410-Q10-QMay 1, 20248-KResults of OperationsMay 1, 2024DEFA14ADEFA14AApr 10, 2024DEF 14ADEF 14AApr 10, 202410-K10-KFeb 9, 20248-KResults of OperationsFeb 7, 20248-KCompany UpdateNov 13, 20238-KCompany UpdateNov 9, 202310-Q10-QOct 31, 20238-KResults of OperationsOct 31, 20238-KCompany UpdateOct 6, 20238-KCompany UpdateOct 5, 20238-KCompany UpdateSep 12, 202310-Q10-QAug 1, 20238-KResults of OperationsAug 1, 20238-KExecutive ChangeJul 13, 20238-KExecutive Change · Bylaw AmendmentJul 12, 20238-KExecutive Change · Shareholder VoteMay 19, 202310-Q10-QMay 3, 20238-KResults of OperationsMay 3, 2023DEFA14ADEFA14AMay 2, 2023DEFA14ADEFA14AApr 5, 2023DEF 14ADEF 14AApr 5, 20238-KCompany UpdateMar 29, 20238-KCompany UpdateFeb 24, 20238-KBylaw AmendmentFeb 10, 202310-K10-KFeb 9, 20238-KResults of OperationsFeb 6, 20238-KMaterial AgreementJan 9, 202310-Q10-QNov 1, 20228-KResults of OperationsNov 1, 20228-KReg FD DisclosureAug 30, 202210-Q10-QAug 4, 20228-KResults of OperationsAug 4, 20228-KCompany UpdateJun 1, 20228-KCompany UpdateMay 25, 20228-KExecutive Change · Shareholder VoteMay 23, 202210-Q10-QMay 4, 20228-KResults of OperationsMay 4, 2022DEFA14ADEFA14AApr 7, 2022DEF 14ADEF 14AApr 7, 202210-K10-KFeb 11, 20228-KResults of OperationsFeb 11, 20228-KResults of OperationsJan 6, 20228-KCompany UpdateDec 23, 20218-KMaterial AgreementNov 22, 2021

Insider Activity

In the 90 days to Jan 16, 2026: 7 sold $14.6M.

DateInsiderActionSharesPriceValue
Jan 16, 2026Gano KyleChief Executive OfficerSell34,588$132.70$4.6M
Jan 16, 2026Gano KyleChief Executive OfficerSell1,812$132.71$240K
Dec 16, 2025Norwalk Leslie VDirectorSell1,190$155.09$185K
Dec 15, 2025Norwalk Leslie VDirectorSell5,000$152.23$761K
Dec 8, 2025Lippoldt DarinChief Legal OfficerSell4,376$159.65$699K
Dec 3, 2025Lyons Gary ADirectorSell15,000$152.61$2.3M
Nov 28, 2025Benevich EricChief Commercial OfficerSell5,970$151.74$906K
Nov 25, 2025Morrow George JDirectorSell15,000$143.37$2.2M
Nov 5, 2025Rastetter William HDirectorSell18,000$151.82$2.7M
Nov 4, 2025Gano KyleChief Executive OfficerSell300$141.97$43K

Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.

In the News

Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗

Similar companies

Comparable business profile · signals at a glance